Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE (NASDAQ:VALN)’s share price gapped up prior to trading on Monday . The stock had previously closed at $7.44, but opened at $8.01. Valneva shares last traded at $7.77, with a volume of 53,450 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price target on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 19th.

Valneva Stock Down 5.1 %

The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The firm has a market capitalization of $602.14 million, a PE ratio of -57.00 and a beta of 1.98. The business’s 50 day moving average price is $5.41 and its 200-day moving average price is $5.67.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. ABC Arbitrage SA acquired a new stake in shares of Valneva in the fourth quarter valued at $84,000. AlphaCentric Advisors LLC boosted its holdings in Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after acquiring an additional 29,748 shares during the period. Finally, Wells Fargo & Company MN grew its position in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after acquiring an additional 30,859 shares in the last quarter. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.